bioquiddity logo link to home page

Mark Ehlert
Non-Executive Director
Mr. Ehlert started his career in 1975 with Baxter Healthcare and continued there for more than 20 years, until he joined Allegiance Healthcare where he was a corporate officer responsible for Quality, Regulatory and R&D. During his time at Baxter, he worked in manufacturing operations for IV fluids, injectable drugs, simple medical devices and electronic infusion devices, and spent time expanding Baxter’s presence in Asia. At Baxter, Mr. Ehlert had P&L responsibility for a major hub of Asian operations. Most recently, Mr. Ehlert retired as Corporate Vice President for Global Quality and Regulatory at Hospira, a global market leader for generic injectable pharmaceuticals and medication management systems.

N. William Jasper Jr.
Non-Executive Director
Mr. Jasper was the CEO and President of Dolby Laboratories until his retirement in 2009. He led Dolby through its evolution as a small technology innovator, to an international leader and brand name in the technology industry. Mr. Jasper was CEO during Dolby’s Initial Public Offering in 2005. BioQuiddity believes Mr. Jasper brings significant experience in financing, corporate governance, and technology licensing.

Llew Keltner, MD, Ph.D.
Non-Executive Director
Dr. Keltner is Chairman of Raptor Pharmaceuticals (RPTP). Dr. Keltner has been working in the Biotech industry for more than 30 years and is considered an expert in immunology. He has served as the CEO of AgonOx, President of Novici Biotech, the CEO of Light Sciences Oncology, and the CEO of Metastat. He has also served on, or is currently serving on, the Boards of MannKind Corporation, Immunovaccine, Infostat, Oregon Life Sciences, and Goodwell Technologies. Dr. Keltner is well-connected in the biotech community and we believe his demonstrated talent for developing strategic business partnerships is of great benefit to BioQuiddity.

Josh Kriesel, Ph.D.
CEO and Director
Dr. Kriesel is co-founder of BioQuiddity and is responsible for executing and coordinating major aspects of the financing, technical, and business development activities. He earned his Ph.D. in Chemistry from the University of California at Berkeley and previously served in a variety of management roles at a medical device company in Silicon Valley. Dr. Kriesel also serves as a non-executive director of a chemical company developing, manufacturing and selling antimicrobial additives and coatings for use in the pharmaceutical, medical and consumer healthcare industries.

Richard Nesbit, Ph.D.
Non-Executive Director
Dr. Nesbit is the retired Vice President of Advanced Technology and Vice President of Quality Assurance at Beckman Instruments (now Beckman-Coulter a subsidiary of Danaher), a multinational corporation that designs, manufactures, and sells biomedical testing instrumentation for clinical laboratories. Dr. Nesbit played a vital role in growing Beckman Instruments from a scientific instrument company with small medical technology business into a leading global diagnostics business, with current revenues in excess of US $2.5 billion.

Viscount Christopher Portman
Non-Executive Director
Lord Portman is Chairman of the Portman Settled Estate Ltd, which manages 110 acres in central London. Under Viscount Portman's leadership, the Portman Estate has undertaken multi-million pound investments in the improvement of buildings across their properties. Lord Portman is an experienced medical technology investor whose diverse interests include nanotechnology, pharmaceuticals, stem-cells and medical devices.

Daniel Tassé
Non-Executive Director
Mr. Tassé was formerly the President and Chief Executive Officer and Chairman of the board of directors of Ikaria, which was sold in April 2015 to Mallinckrodt for $2.3 billion. Prior to Ikaria, Mr. Tassé was the General Manager of the Pharmaceuticals and Technologies Business Unit of Baxter International, Inc., and Vice President and Regional Director for Australasia at GlaxoSmithKline. He currently serves on the board of several publicly traded companies, including Bellerophon Therapeutics and Indivior PLC, a company traded on the London Stock Exchange. Mr. Tassé was a member of the Healthcare Leadership Council (2010 to June 2015) and of the Health Section Governing Board of the Biotechnology Industry Organization (2011 to June 2015), where he participated on the bioethics, regulatory environment and reimbursement committees. Mr. Tassé received a B.S. in biochemistry from the University of Montreal.